About
The Xcel Prototypes of Proprietary Clinical-Grade Human Stem Cell Therapy Products Provide Future Medicine for CNS and Heart Regeneration in Unmet Medical Needs: Their Xcel prototypes, generated from human ES cells using their novel PluriXcel technology, currently include Xcel-hNuP (human neuronal progenitors), Xcel-hNu (human neurons), Xcel-hCardP (human heart precursors), Xcel-hCM (human heart muscle cells), which are the only available human cell sources in commercial scales with adequate cellular pharmacologic utility and capacity to regenerate the CNS neurons and contractile heart muscles, vital for CNS and heart repair for a wide range of neurological and cardiovascular diseases in the clinical setting. They believe that their Xcel prototypes represent the next generation of human cell therapy products, offering purity, large-scale production, high quality, safety, and effectiveness for commercial and therapeutic uses over all other existing human cell sources.
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 829 investors are based in San Diego, California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- San Diego, US
Contact Information
Find more investors like Xcelthera
Search Investors